adenosine diphosphate has been researched along with ticagrelor in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (12.90) | 29.6817 |
| 2010's | 37 (59.68) | 24.3611 |
| 2020's | 17 (27.42) | 2.80 |
| Authors | Studies |
|---|---|
| Humphries, RG; van Giezen, JJ | 1 |
| Dai, J; Houard, X; Louedec, L; Michel, JB; Philippe, M | 1 |
| Erlinge, D; Eyjolfsson, A; Gustafsson, R; Högberg, C; Svensson, H | 1 |
| Husted, S | 1 |
| Berntsson, P; Giordanetto, F; Greasley, PJ; Nilsson, L; Tomlinson, W; VAN Giezen, JJ; Wissing, BM | 1 |
| Husted, S; van Giezen, JJ | 1 |
| Armstrong, M; Cannon, CP; Emanuelsson, H; Heptinstall, S; Husted, S; Lawrance, R; Melissa Thornton, S; Storey, RF; Wickens, M | 1 |
| del Río, A; Heras, M | 1 |
| Cattaneo, M | 2 |
| Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; White, AE | 1 |
| Jilma, B; Siller-Matula, JM | 1 |
| De Mey, JG; Feijge, MA; Heemskerk, JW; Kuijpers, MJ; Megens, RT; Nikookhesal, E; oude Egbrink, MG; van Giezen, JJ | 1 |
| Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM | 1 |
| Kong, L; Liu, J; Sun, H; Yao, H; Zhang, H; Zhang, L | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Gkizas, V; Hahalis, G; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Butler, K; Maya, J; Teng, R | 1 |
| Fabiszak, T; Grzesk, E; Grześk, G; Gurbel, PA; Jeong, YH; Kozinski, M; Kubica, J; Navarese, EP; Tantry, US; Wicinski, M | 1 |
| Jakubowski, JA; Mizuno, M; Ohno, K; Sugidachi, A; Tomizawa, A | 1 |
| Derhaschnig, U; Firbas, C; Hobl, EL; Jilma, B; Schoergenhofer, C; Schwameis, M | 1 |
| Albertsson, P; Åström-Olsson, K; Dellborg, M; Hansson, EC; Hesse, C; Jeppsson, A; Shams Hakimi, C; Wallén, H | 1 |
| Chen, XP; Li, MP; Tang, J; Xiong, Y; Xu, A; Zhang, W; Zhang, ZL; Zhou, HH; Zhou, JP | 1 |
| Baqi, Y; Hoffmann, K; Lutz, DA; Müller, CE; Straßburger, J; von Kügelgen, I | 1 |
| Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L | 1 |
| de Groot, PG; de Mast, Q; Dinarello, CA; Fijnheer, R; Gasem, MH; Gomes, ME; Joosten, LA; Netea, MG; Riksen, N; Rongen, G; Tacke, S; Tunjungputri, RN; van de Veerdonk, FL; van den Berg, TN; van der Ven, AJ | 1 |
| Honda, Y; Morishima, Y | 1 |
| Chen, XP; Li, MP; Tang, J; Wen, ZP; Zhang, W; Zhang, YJ; Zhang, ZL; Zhou, HH | 1 |
| Bachelot-Loza, C; Berndt, C; Calmette, L; Decouture, B; Gaussem, P; Godier, A; Gouin-Thibault, I; Martin, AC; Philip, I; Samama, CM | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 2 |
| Akca, B; Berger, R; Delle-Karth, G; Kreiner, G; Lang, IM; Maurer, G; Neunteufl, T; Siller-Matula, JM | 1 |
| Bernlochner, I; Gross, L; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Orban, M; Rössner, L; Sibbing, D | 1 |
| Barbieri, L; Bellomo, G; Daffara, V; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Åkesson, J; Andersson, M; Hansson, EC; Hesse, C; Jeppsson, A; Malm, CJ; Shams Hakimi, C | 1 |
| Aungraheeta, R; Butler, M; Conibear, A; Kelly, E; Mumford, A; Mundell, SJ; Nylander, S | 1 |
| Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME | 1 |
| Holm, M; Rihan Hye, S; Tornvall, P; van der Linden, J; Westerberg, J | 1 |
| Almquist, J; Gennemark, P; Goodman, J; Janefeldt, A; Johansson, KJ; Maqbool, S; Nylander, S; Pehrsson, S; Sanchez, J; Sandinge, AS | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM | 1 |
| Ćwiek, A; Filipiak, KJ; Gasecka, A; Hajji, N; Konwerski, M; Nieuwland, R; Pluta, K; van der Pol, E | 1 |
| Davani, S; Haghighi, F; Pais-De-Barros, JP; Rabani, V | 1 |
| Bhagirath, VC; Chan, NC; Dale, B; de Vries, TAC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Kruger, PC; Xu, K | 1 |
| Eikelboom, JW; Fan, Y; Li, C; Li, J; Mei, L; Niles, K; Wang, F; Xu, K; Yang, L; Zhang, J; Zhang, S; Zhu, H; Zou, F | 1 |
| Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP | 1 |
| Guo, L; Huang, Q; Shi, X; Wang, G; Yang, Y; Yuan, D; Yuan, Y; Zhang, H; Zhao, Y | 1 |
| Gremmel, T; Hoberstorfer, T; Kopp, CW; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Che, J; Chen, K; Dou, S; Liu, H; Liu, X; Wang, W; Wang, X; Zhang, X; Zhou, X | 1 |
| Bliden, KP; Dahlen, J; Fisher, R; Gurbel, PA; Speros, PC; Sukavaneshvar, S; Tantry, US | 1 |
| Alfaro, E; Cubillos-Zapata, C; Díaz-García, E; Galera, R; García-Rio, F; García-Tovar, S; López-Collazo, E; Mangas, A; Nanwani-Nanwani, K; Pérez-de-Diego, R; Rodríguez-Gallego, C; Ruíz-Hernández, JJ; Solé-Violán, J; Van-Den-Rym, A; Zamarrón, E | 1 |
| Friebel, J; Hassanein, A; Jakobs, K; Landmesser, U; Puccini, M; Rauch, C; Rauch, U | 1 |
| Aguiar, MO; Azevedo, L; Baracioli, LM; Berwanger, O; Chiang, HP; Dalcoquio, TF; de Luca, F; Ferrari, AG; Furtado, RHM; Giugliano, RP; Goodman, S; Lima, FG; Matthias, W; Menezes, FR; Nicolau, JC; Scanavini-Filho, MA | 1 |
| Li, X; Lv, Q; Wang, Z; Xia, L; Yao, Y; Ye, Y; Zou, Y | 1 |
| Han, X; He, M; Kong, Y; Li, Y; Liu, G; Ren, J; Shi, J; Yan, W; Zhang, Y; Zhao, Z | 1 |
| Costa, TGR; Franken, M; Guerra, JCC; Katz, M; Lemos Neto, PA; Pesaro, AEP | 1 |
| Bogo, MR; Cappellari, AR; de Fraga Dias, A; Diz, FM; Figueiró, F; Filippi-Chiela, EC; Grave, N; Kist, LW; Leal, GF; Lenz, G; Morrone, FB; Rockenbach, L; Scheffel, TB; Thomé, MP; Vargas, P | 1 |
| Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM | 1 |
| Han, K; Huang, X; Ma, M; Sun, T; Yang, S; Zhao, Z; Zhou, Y | 1 |
| Ding, LP; Do, HP; Ge, WH; Li, YC; Liu, T; Shao, TF; Wang, R; Xu, MM; Yi, MM; Zhuang, Z | 1 |
| Baron, SJ; Dani, SS; Ganatra, S; Ijaz, SH; Kulbak, G; Levy, M; Resnic, F; Shahnawaz, A | 1 |
| Amaradasa, K; Bancroft, S; Dimofte, T; Hindle, MS; Hutchinson, JL; Johnson, T; Keith, M; Khalil, J; Mundell, SJ; Naseem, K; Roberts, T | 1 |
8 review(s) available for adenosine diphosphate and ticagrelor
| Article | Year |
|---|---|
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Animals; Arterial Occlusive Diseases; Clinical Trials as Topic; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Female; Fibrinolytic Agents; Humans; Injections, Intravenous; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Rabbits; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor | 2005 |
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Vasoconstriction | 2009 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor: from discovery to Phase III clinical trial.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Utilization Trends In Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor and Cost Among Medicare Beneficiaries.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Humans; Medicare; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; United States | 2023 |
13 trial(s) available for adenosine diphosphate and ticagrelor
| Article | Year |
|---|---|
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Topics: Adenosine; Adenosine Diphosphate; Area Under Curve; Atherosclerosis; Clopidogrel; Dose-Response Relationship, Drug; Humans; Integrin beta3; Pharmacogenetics; Platelet Aggregation; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2013 |
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses.
Topics: Adenosine; Adenosine Diphosphate; Adult; Blood Platelets; Cross-Over Studies; Cytokines; Double-Blind Method; Humans; Inflammation; Leukocytes, Mononuclear; Ligands; Lipopolysaccharides; Male; Monocytes; Phagocytosis; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; RNA, Messenger; Ticagrelor; Toll-Like Receptor 2; Toll-Like Receptor 4; Young Adult | 2015 |
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
Topics: Adenosine; Adenosine Diphosphate; Aged; Biotransformation; Blood Platelets; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Sweden; Ticagrelor | 2017 |
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor | 2018 |
In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Blood Platelets; Cells, Cultured; Female; Healthy Volunteers; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Platelet-Rich Plasma; Risk; Thrombosis; Ticagrelor; Young Adult | 2018 |
Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Transfusion; Ticagrelor; Young Adult | 2019 |
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction.
Topics: Adenosine Diphosphate; Clopidogrel; Humans; Microcirculation; Myocardial Infarction; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study).
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Epinephrine; Fibrinolytic Agents; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor | 2022 |
41 other study(ies) available for adenosine diphosphate and ticagrelor
| Article | Year |
|---|---|
Molecule of the month. Ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Cardiovascular Diseases; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor | 2007 |
Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model.
Topics: Adenosine; Adenosine Diphosphate; Animals; Aorta; Aortic Aneurysm, Abdominal; Blood Platelets; Disease Models, Animal; Disease Progression; Elastic Tissue; Guinea Pigs; Inflammation; Male; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rats; Rats, Inbred Lew; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Time Factors; Transplantation, Heterologous | 2009 |
The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature.
Topics: Adenosine; Adenosine Diphosphate; Administration, Oral; Aged; Animals; Aorta, Thoracic; Female; Humans; Male; Mammary Arteries; Mice; Receptors, Purinergic P2Y12; Species Specificity; Ticagrelor; Vasoconstriction; Vasoconstrictor Agents | 2010 |
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.
Topics: Adenosine; Adenosine Diphosphate; Animals; Binding Sites; Blood Platelets; Cell Membrane; CHO Cells; Cricetinae; Cricetulus; Humans; Kinetics; Platelet Aggregation; Protein Binding; Pyrimidines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Signal Transduction; Ticagrelor | 2009 |
Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Erythrocytes; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor | 2011 |
Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Cytoprotection; Platelet Activation; Protein Binding; Purinergic P2Y Receptor Antagonists; Rats; Rats, Inbred WKY; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelets; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rats; Receptors, Purinergic P2Y12; Structure-Activity Relationship; Ticagrelor | 2012 |
Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Young Adult | 2013 |
High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Aspirin; Dose-Response Relationship, Drug; Endothelium, Vascular; Male; Muscle Contraction; Myocytes, Smooth Muscle; Rats; Tail; Ticagrelor; Vasoconstriction | 2013 |
Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
Topics: Adenosine; Adenosine Diphosphate; Administration, Oral; Adult; Animals; Cell Adhesion Molecules; Clinical Protocols; Enzyme-Linked Immunosorbent Assay; Humans; Macaca fascicularis; Male; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Young Adult | 2013 |
Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Adult; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet-Rich Plasma; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2013 |
Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Ticagrelor; Ticlopidine | 2014 |
Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Topics: Adenosine; Adenosine Diphosphate; Adult; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Humans; Integrin alpha2; Integrin beta3; Male; Platelet Aggregation; Polymorphism, Single Nucleotide; Purinergic P2 Receptor Antagonists; Ticagrelor; Young Adult | 2014 |
Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Topics: Adenosine; Adenosine Diphosphate; Animals; Binding Sites; Binding, Competitive; CHO Cells; Colforsin; Cricetulus; Cyclic AMP; Dose-Response Relationship, Drug; Gene Expression Regulation; Genes, Reporter; Humans; Luciferases; Mutation; Platelet Aggregation Inhibitors; Protein Binding; Purinergic P2Y Receptor Agonists; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Response Elements; Thionucleotides; Ticagrelor; Transfection | 2014 |
Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
Topics: Adenosine; Adenosine Diphosphate; Blood Coagulation; Blood Coagulation Tests; Factor Xa Inhibitors; Humans; Platelet-Rich Plasma; Purinergic P2Y Receptor Antagonists; Pyridines; Thiazoles; Thrombin; Thromboplastin; Ticagrelor | 2015 |
Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Topics: Adenosine; Adenosine Diphosphate; Adolescent; Adult; Alleles; Asian People; Blood Platelets; Drug Antagonism; Genotype; Healthy Volunteers; Heterotrimeric GTP-Binding Proteins; Humans; Male; Platelet Activation; Platelet Aggregation; Platelet-Rich Plasma; Polymorphism, Single Nucleotide; Primary Cell Culture; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Sequence Analysis, DNA; Ticagrelor | 2015 |
The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study.
Topics: Adenosine; Adenosine Diphosphate; Arachidonic Acid; Aspirin; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Ticagrelor | 2016 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Patient Discharge; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Biomarkers; Blood Platelets; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Risk Factors; Ticagrelor; Treatment Outcome | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation | 2016 |
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Vitamin D | 2016 |
Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study.
Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Blood Platelets; Cardiac Surgical Procedures; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Transfusion; Postoperative Hemorrhage; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Calcium; Calcium Signaling; Cell Adhesion Molecules; Colforsin; Cyclic AMP; Equilibrative Nucleoside Transporter 1; Female; Humans; Male; Microfilament Proteins; Phosphoproteins; Phosphorylation; Platelet Activation; Receptors, Purinergic P2Y12; Ticagrelor | 2016 |
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Patient Preference; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin.
Topics: Adenosine; Adenosine Diphosphate; Animals; Antibodies, Neutralizing; Antidotes; Aspirin; Biotinylation; Blood Pressure; Broadly Neutralizing Antibodies; Hemorrhage; Hemostasis; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Swine; Ticagrelor; Time Factors | 2017 |
Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Topics: Adenosine; Adenosine Diphosphate; Aged; Anemia; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine | 2018 |
P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Topics: Adenosine Diphosphate; Blood Coagulation; Blood Platelets; Extracellular Vesicles; Healthy Volunteers; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Signal Transduction; Ticagrelor | 2019 |
Reorganization of platelet membrane sphingomyelins by adenosine diphosphate and ticagrelor.
Topics: Adenosine Diphosphate; Cell Membrane; Sphingomyelins; Ticagrelor | 2018 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Stroke; Survival Rate; Ticagrelor | 2020 |
Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Genotype; Glutathione S-Transferase pi; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Retrospective Studies; Ticagrelor | 2020 |
Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C9; Female; Genotype; Humans; Hyperuricemia; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thienopyridines; Ticagrelor; Ticlopidine; Uric Acid | 2021 |
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y
Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Apyrase; Biomarkers; Blood Platelets; Cell Hypoxia; COVID-19; Critical Care; Female; Humans; Influenza A virus; Influenza, Human; Length of Stay; Male; Middle Aged; Platelet Activation; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; SARS-CoV-2; Severity of Illness Index; Signal Transduction; Thromboinflammation; Ticagrelor | 2022 |
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2023 |
Does thromboelastography predict bleeding in patients treated with clopidogrel or ticagrelor in off-pump coronary artery bypass grafting?
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Thrombelastography; Ticagrelor | 2022 |
Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor.
Topics: Adenosine Diphosphate; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
P2Y
Topics: Adenosine Diphosphate; Autophagy; Blood Platelets; Cell Proliferation; Glioblastoma; Humans; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor | 2022 |
Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.
Topics: Adenosine; Adenosine Diphosphate; Clopidogrel; Complement C1q; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Ticlopidine | 2022 |
Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Unruptured Intracranial Aneurysm Treated with Stent-Assisted Coil Embolization: A Single-Center Cohort Study.
Topics: Adenosine Diphosphate; Clopidogrel; Cohort Studies; Embolization, Therapeutic; Fibrinogen; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Stents; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor inverse agonist activity at the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Blood Platelets; Diphosphates; Drug Inverse Agonism; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor | 2024 |